{
    "clinical_study": {
        "@rank": "137680", 
        "acronym": "Regent Vsel", 
        "arm_group": [
            {
                "arm_group_label": "CD133+", 
                "arm_group_type": "Experimental", 
                "description": "intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the efficacy of therapy with autological CD133+\n      cells in patients with angina resistant to pharmacological treatment and without the\n      possibility of effective revascularization. Cells will be isolated from patients bone marrow\n      and administered directly into the muscle of left ventricle. The main objective is to assess\n      the treatments' influence on improvement of myocardial perfusion and function, and on\n      decrease of occurrence of symptomatic angina."
        }, 
        "brief_title": "Intracardiac CD133+ Cells in Patients With No-option Resistant Angina", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Stable Angina", 
        "condition_browse": {
            "mesh_term": "Angina Pectoris"
        }, 
        "detailed_description": {
            "textblock": "Patients with a Stable angina pectoris (CCS II-IV) can potentially benefit from treatment\n      with autological CD133+ cell populations, which include cells with a higher expression of\n      cardiac and endothelial differentiation markers.\n\n      REGENT VSEL Trial will include Patients with Angina resistant to pharmacological treatment\n      and without the possibility of effective revascularization.\n\n      The main objective of the study is to assess the treatments influence on:\n\n        -  improvement of myocardial perfusion\n\n        -  global and segmental contractility (LVEF)\n\n        -  occurrence of symptomatic angina\n\n        -  quality of life\n\n      Regent Vsel is a prospective, randomized, double blind, placebo-controlled study with a\n      planned number of 60 Patients.\n\n      Randomization will be carried out according to a 1:1 mode. Every Patient will undergo a bone\n      marrow aspiration. CD133+ cells will be isolated from bone marrow aspirates. Patients\n      randomized to experimental group will receive isolated cells (direct left ventricular muscle\n      administration). Patients enrolled to control group will get only a placebo solution\n      injected into the muscle."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Stable angina CCS II-IV despite maximum pharmacotherapy for at least 2   weeks since\n             last medications change\n\n          2. Presence of \u2265 1 myocardial segment with ischemia features in Tc-99m SPECT\n\n          3. Patients disqualified from revascularization procedures by Heart Team\n\n          4. Patient age > 18 and < 75 year old\n\n          5. Patient must provide written informed consent for participation in study\n\n        Exclusion Criteria:\n\n          1. Acute coronary syndrome in less than 6 months prior to enrollment\n\n          2. Heart failure NYHA III-IV\n\n          3. LVEF <35%\n\n          4. Presence of intracardiac thrombus (echocardiography confirmed), massive calcification\n             of the aortic valve and left ventricular aneurysm\n\n          5. Previous cardioverter-defibrillator or cardiac stimulator implantation\n\n          6. Allergy to contrast agents\n\n          7. History of malignancy\n\n          8. HIV, HBV, HCV infection\n\n          9. Life expectancy less than 6 months\n\n         10. Bleeding diathesis\n\n         11. Renal insufficiency (GFR < 30 mL/min/1.73m2)\n\n         12. Pregnancy, lactation, or ineffective contraception in women of childbearing potential"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660581", 
            "org_study_id": "Regent Vsel", 
            "secondary_id": "2011-005435-98"
        }, 
        "intervention": [
            {
                "arm_group_label": "CD133+", 
                "description": "Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.", 
                "intervention_name": "intramyocardial injection (electromechanical mapping based)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "CD133+", 
            "stem cells", 
            "Coronary Artery Disease", 
            "Stable Angina Pectoris"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "contact": {
                "email": "wojtek.wojakowski@gmail.com", 
                "last_name": "Wojciech Wojakowski, MD, PhD", 
                "phone": "+48 32 2523930"
            }, 
            "facility": {
                "address": {
                    "city": "Katowice-Ochojec", 
                    "country": "Poland", 
                    "state": "Silesian", 
                    "zip": "40-635"
                }, 
                "name": "Samodzielny Publiczny Szpital Kliniczny nr 7 \u015al\u0105skiego Uniwersytetu Medycznego w Katowicach G\u00f3rno\u015bl\u0105skie Centrum Medyczne im. prof. Leszka Gieca"
            }, 
            "investigator": {
                "last_name": "Wojciech Wojakowski, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Prospective, Double-blind Study to Evaluate Intracardiac Injections of Bone Marrow, Autologous CD133+ Cells (Electromechanical Mapping Based) in Patients With Resistant Angina and no Effective Revascularization Option. Regent Vsel Study.", 
        "overall_contact": {
            "email": "wojtek.wojakowski@gmail.com", 
            "last_name": "Wojciech Wojakowski, MD, PhD", 
            "phone": "+48 32 2523930"
        }, 
        "overall_official": {
            "affiliation": "Samodzielny Publiczny Szpital Kliniczny nr 7 \u015al\u0105skiego Uniwersytetu Medycznego w Katowicach G\u00f3rno\u015bl\u0105skie Centrum Medyczne III Klinika Kardiologii", 
            "last_name": "Wojciech Wojakowski, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Poland: Komisja Bioetyczna Slaski Uniwersytet Medyczny", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Myocardial perfusion change assessed by perfusion scintigraphy (99mTc SPECT)", 
            "measure": "Myocardial perfusion change", 
            "safety_issue": "No", 
            "time_frame": "4 months after application of cell therapy"
        }, 
        "reference": [
            {
                "PMID": "17533201", 
                "citation": "Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007 May 28;167(10):989-97. Review."
            }, 
            {
                "PMID": "17964040", 
                "citation": "Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, Vanderheyden M, Kim HS, Kang HJ, Strauer BE, Vetrovec GW. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007 Oct 30;50(18):1761-7. Epub 2007 Oct 15. Review."
            }, 
            {
                "PMID": "16267071", 
                "citation": "Wojakowski W, Tendera M, Zebzda A, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Krol M, Ochala A, Kozakiewicz K, Ratajczak MZ. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J. 2006 Feb;27(3):283-9. Epub 2005 Nov 2."
            }, 
            {
                "PMID": "15533859", 
                "citation": "Wojakowski W, Tendera M, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Ochala A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation. 2004 Nov 16;110(20):3213-20. Epub 2004 Nov 8."
            }, 
            {
                "PMID": "19454638", 
                "citation": "van Ramshorst J, Bax JJ, Beeres SL, Dibbets-Schneider P, Roes SD, Stokkel MP, de Roos A, Fibbe WE, Zwaginga JJ, Boersma E, Schalij MJ, Atsma DE. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA. 2009 May 20;301(19):1997-2004."
            }, 
            {
                "PMID": "17951319", 
                "citation": "Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):208-16. Epub 2007 Oct 19. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660581"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Silesia", 
            "investigator_full_name": "Wojciech Wojakowski MD, PhD", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Global and segmental contractility change and myocardial perfusion change assessed by magnetic resonance imaging with adenosine administration, and echocardiography with contrast", 
                "measure": "Global and segmental contractility change and myocardial perfusion change", 
                "safety_issue": "No", 
                "time_frame": "MRI 4 months and echocardiography 4 and 12 months after application of cell therapy"
            }, 
            {
                "description": "Exercise tolerance assessed in a treadmill test (TET, ESTD, TTLA)", 
                "measure": "Exercise tolerance", 
                "safety_issue": "No", 
                "time_frame": "4 and 12 months after application of cell therapy"
            }, 
            {
                "description": "CCS, nitrates usage", 
                "measure": "Occurrence of symptomatic angina", 
                "safety_issue": "Yes", 
                "time_frame": "1, 4, 6 and 12 months after application of cell therapy"
            }, 
            {
                "description": "Quality of life assessed by standard questionnaires: SF37, Seattle Angina", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "1, 4, 6 and 12 months after application of cell therapy"
            }, 
            {
                "description": "24 hrs ECG monitoring", 
                "measure": "Occurrence of ventricular arrhythmia", 
                "safety_issue": "Yes", 
                "time_frame": "1, 4, 6 and 12 months after application of cell therapy"
            }, 
            {
                "description": "Assessed by Intravascular Ultrasound (IVUS) and Optical coherence tomography (OCT) examination", 
                "measure": "Occurrence of in-stent restenosis and progression of artherosclerotic lesions in remained coronary artery segments", 
                "safety_issue": "Yes", 
                "time_frame": "4 months after application of cell therapy"
            }
        ], 
        "source": "Medical University of Silesia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Silesia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}